Literature DB >> 18809758

Down-regulation of hepcidin in porphyria cutanea tarda.

Richard S Ajioka1, John D Phillips, Robert B Weiss, Diane M Dunn, Maria W Smit, Sean C Proll, Michael G Katze, James P Kushner.   

Abstract

Hepatic siderosis is common in patients with porphyria cutanea tarda (PCT). Mutations in the hereditary hemochromatosis (hh) gene (HFE) explain the siderosis in approximately 20% patients, suggesting that the remaining occurrences result from additional genetic and environmental factors. Two genes known to modify iron loading in hh are hepcidin (HAMP) and hemojuvelin (HJV). To determine if mutations in or expression of these genes influenced iron overload in PCT, we compared sequences of HAMP and HJV in 96 patients with PCT and 88 HFE C282Y homozygotes with marked hepatic iron overload. We also compared hepatic expression of these and other iron-related genes in a group of patients with PCT and hh. Two intronic polymorphisms in HJV were associated with elevated serum ferritin in HFE C282Y homozygotes. No exonic polymorphisms were identified. Sequencing of HAMP revealed exonic polymorphisms in 2 patients with PCT: heterozygosity for a G-->A transition (G71D substitution) in one and heterozygosity for an A-->G transition (K83R substitution) in the other. Hepatic HAMP expression in patients with PCT was significantly reduced, regardless of HFE genotype, when compared with patients with hh but without PCT with comparable iron overload. These data indicate that the hepatic siderosis associated with PCT likely results from dysregulated HAMP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809758      PMCID: PMC2597139          DOI: 10.1182/blood-2008-02-138222

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  The human genome browser at UCSC.

Authors:  W James Kent; Charles W Sugnet; Terrence S Furey; Krishna M Roskin; Tom H Pringle; Alan M Zahler; David Haussler
Journal:  Genome Res       Date:  2002-06       Impact factor: 9.043

2.  Global prevalence of putative haemochromatosis mutations.

Authors:  A T Merryweather-Clarke; J J Pointon; J D Shearman; K J Robson
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

3.  Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.

Authors:  Z J Bulaj; J D Phillips; R S Ajioka; M R Franklin; L M Griffen; D J Guinee; C Q Edwards; J P Kushner
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

4.  Metabolic basis of diethylaminoethoxyhexestrol-induced phospholipid fatty liver.

Authors:  M Kubo; K Y Hostetler
Journal:  Am J Physiol       Date:  1987-03

5.  Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

Authors:  Ernest Beutler; Vincent J Felitti; James A Koziol; Ngoc J Ho; Terri Gelbart
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

6.  Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol.

Authors:  Duygu Dee Harrison-Findik; Elizabeth Klein; Callie Crist; John Evans; Nikolai Timchenko; John Gollan
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

7.  The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype.

Authors:  Gérald Le Gac; Virginie Scotet; Chandran Ka; Isabelle Gourlaouen; Laurence Bryckaert; Sandrine Jacolot; Catherine Mura; Claude Férec
Journal:  Hum Mol Genet       Date:  2004-07-14       Impact factor: 6.150

8.  Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis.

Authors:  Jacob George; Natasha Pera; Nghi Phung; Isabelle Leclercq; Jing Yun Hou; Geoffrey Farrell
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

Review 9.  Non-HFE haemochromatosis.

Authors:  Daniel-F Wallace; V-Nathan Subramaniam
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

10.  Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.

Authors:  Naoki Fujita; Ryosuke Sugimoto; Masaki Takeo; Naohito Urawa; Rumi Mifuji; Hideaki Tanaka; Yoshinao Kobayashi; Motoh Iwasa; Shozo Watanabe; Yukihiko Adachi; Masahiko Kaito
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

View more
  7 in total

Review 1.  Heme biosynthesis and the porphyrias.

Authors:  John D Phillips
Journal:  Mol Genet Metab       Date:  2019-04-22       Impact factor: 4.797

Review 2.  Recent advances in iron metabolism and related disorders.

Authors:  Clara Camaschella; Paolo Strati
Journal:  Intern Emerg Med       Date:  2010-04-28       Impact factor: 3.397

Review 3.  Iron overload cardiomyopathy: better understanding of an increasing disorder.

Authors:  Pradeep Gujja; Douglas R Rosing; Dorothy J Tripodi; Yukitaka Shizukuda
Journal:  J Am Coll Cardiol       Date:  2010-09-21       Impact factor: 24.094

Review 4.  Hepatitis C, porphyria cutanea tarda and liver iron: an update.

Authors:  F Ryan Caballes; Hossein Sendi; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2012-04-17       Impact factor: 5.828

5.  Porphyria cutanea tarda associated with HFE C282Y homozygosity, iron overload, and use of a contraceptive vaginal ring.

Authors:  James C Barton; Corwin Q Edwards
Journal:  J Community Hosp Intern Med Perspect       Date:  2016-02-17

Review 6.  Iron in Porphyrias: Friend or Foe?

Authors:  Elena Buzzetti; Paolo Ventura; Elena Corradini
Journal:  Diagnostics (Basel)       Date:  2022-01-21

7.  The D519G Polymorphism of Glyceronephosphate O-Acyltransferase Is a Risk Factor for Familial Porphyria Cutanea Tarda.

Authors:  Colin P Farrell; Jessica R Overbey; Hetanshi Naik; Danielle Nance; Gordon D McLaren; Christine E McLaren; Luming Zhou; Robert J Desnick; Charles J Parker; John D Phillips
Journal:  PLoS One       Date:  2016-09-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.